Pink Elephant
Venture builder and investment platform for mental-health and psychedelic-care infrastructure.
Website: https://pink-elephant.co/
Cover Block
Public sources
| Name | Pink Elephant |
| Tagline | Venture builder and investment platform for mental-health and psychedelic-care infrastructure. |
| Headquarters | Lisbon, Portugal |
| Founded | 2024 [LinkedIn, retrieved 2026] |
| Stage | Pre-Seed |
| Business Model | Other (Venture Builder / Fund) |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) [Crunchbase] |
Links
Public sources
- Website: https://pink-elephant.co/
- LinkedIn: https://www.linkedin.com/in/filalogic
Lightly corroborated -- Company website confirmed. LinkedIn profile is for co-founder Yuri Filatov; a dedicated company page was not located in the available research.
Executive Summary
Public sources
Pink Elephant is a Lisbon-based venture builder and investment platform aiming to construct the foundational infrastructure for the emerging psychedelic and progressive mental health ecosystem, a bet that hinges on the anticipated regulatory and clinical maturation of novel treatments [Pink Elephant]. Founded in late 2024, the entity positions itself not as a single-product startup but as a multi-pronged operator, simultaneously launching its own ventures, deploying capital through a dedicated fund, and running an accelerator for pre-seed and seed-stage companies [Pink Elephant, Remocate]. Its flagship consumer-facing project, States of Mind, serves as an initial wedge, combining a media platform and provider directory to build trust and navigation tools in a space where reliable information is scarce [LinkedIn, retrieved 2026].
Co-founders Yuri Filatov and Fatima Cabral lead the effort from Portugal, with Filatov citing over 15 years of experience in building from the ground up [Yuri Filatov LinkedIn, retrieved 2026]. The company's operational footprint is suggested by a team that includes a product manager with prior experience scaling a mental-health marketplace supply side to over 300 providers in Europe [LinkedIn, retrieved 2026]. Public financials are minimal, with Portuguese corporate records showing only a €1,000 share capital registration in October 2025; no institutional funding rounds, LP commitments to its venture fund, or a formal valuation have been publicly disclosed [RigorBiz, October 2025].
The next 12-18 months will test the model's viability, requiring clear signals of capital deployment into portfolio companies, tangible user growth for its owned properties like States of Mind, and the formation of verifiable partnerships with clinics or research institutions. Investor attention is warranted for the scale of the ambition in a nascent, capital-intensive sector, but diligence must focus on validating the fund's resources and the team's ability to execute concurrently as builders, investors, and ecosystem catalysts.
Lightly corroborated -- Core company description is from its own materials; team details are corroborated by LinkedIn profiles; incorporation data is from a public registry.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | Other (Venture Builder / Investment Platform) |
| Industry / Vertical | Healthtech |
| Technology Type | Software (Non-AI) |
| Geography | Western Europe (Lisbon, Portugal) |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
How the Company Got Here
Public sources
Pink Elephant is a Lisbon-based venture builder and investment platform incorporated in late 2025, with its founding narrative centered on constructing the underlying infrastructure for a new generation of mental and psychedelic care. The company was formed as Pink Elephant, Unipessoal Lda in Portugal on October 24, 2025, with a registered share capital of €1,000 [RigorBiz, October 2025]. Co-founder Yuri Filatov's public profile dates the company's founding to November 2024, suggesting a period of informal operation prior to formal incorporation [LinkedIn].
Its early milestones are defined by the launch of its stated venture activities and initial product surfaces rather than traditional funding rounds. The company announced a seed investment program for psychedelics startups in May 2024, preceding its own incorporation [Psychedelic Health, May 2024]. By March 2025, it had begun building its operational team, bringing on product managers with relevant marketplace experience [LinkedIn]. The venture's public-facing ecosystem began to take shape with the development of States of Mind, a media and provider-directory platform positioned as a digital-first gateway to progressive mental health information and vetted care options [CB Insights] [LinkedIn].
Lightly corroborated -- Key entity details are documented, but founding timeline and early activities rely on single-source founder profiles and company materials.
Product and Technology
Sources and analysis The core product is a multi-faceted venture-building platform, not a single software application. Pink Elephant's public materials describe an integrated ecosystem focused on building the infrastructure for progressive mental health and psychedelic care [Pink Elephant, October 2026]. This strategy manifests through two primary, overlapping product surfaces: a venture fund and accelerator for external founders, and a collection of internally built consumer and professional tools.
The venture fund component is positioned as a capital and expertise platform for pre-seed and seed-stage companies building in telemedicine, clinic operations, and therapeutic software [Pink Elephant, October 2026]. Alongside this, the company is developing its own products. A central offering is States of Mind, described as a digital-first platform providing information, self-navigation tools, and a provider directory to connect patients with clinics, therapists, and retreat centers [CB Insights]. This platform appears to serve as both a media outlet for psychedelic science and a practical discovery tool [LinkedIn].
Recruiting materials and team profiles suggest a broader technical scope under development, though specific feature launches are not dated. The intended product surface includes diagnostic tools, a curated provider marketplace, and telemedicine capabilities, aiming to cover the patient journey from education to treatment [Remocate, September 2025]. A product manager's background in scaling a mental-health marketplace to over 300 providers hints at the operational experience being applied to these builds, though it does not confirm current deployment [LinkedIn]. The technology stack is not publicly detailed, but the scope implies needs in marketplace dynamics, content management, and potentially telehealth integrations (inferred from job postings).
Public sources The market for progressive mental health and psychedelic care infrastructure is nascent but defined by a convergence of clinical validation, shifting public perception, and a fragmented legacy care system that is straining under demand. Pink Elephant's thesis appears to be that a new ecosystem must be built from the ground up, encompassing everything from patient education to provider discovery, long before treatment modalities are fully legalized or scaled.
Quantifying the total addressable market for this specific infrastructure layer is challenging due to its novelty, but adjacent market sizing provides a useful analog. The global mental health apps market was valued at approximately $5.2 billion in 2022 and is projected to reach $17.5 billion by 2030, according to Grand View Research [Grand View Research, 2023]. The psychedelics therapeutics market, while smaller and more speculative, has seen analyst projections ranging from $6 billion to over $10 billion by the end of the decade, driven by clinical trials for MDMA and psilocybin [Research and Markets, 2023]. These figures represent the end-user therapeutic and digital tool markets; the infrastructure layer Pink Elephant targets,encompassing venture funding, provider marketplaces, diagnostics, and media,would represent a serviceable available market (SAM) carved from within these broader sectors.
Demand drivers are well-documented across third-party research. A persistent global shortage of mental health professionals creates a structural gap in care access [World Health Organization, 2022]. Concurrently, a growing body of peer-reviewed research has demonstrated the potential efficacy of psychedelic-assisted therapies for conditions like treatment-resistant depression and PTSD, legitimizing the field for institutional investors and healthcare systems [Nature Medicine, 2021]. Public acceptance is also shifting, with decriminalization and medical-use initiatives advancing in regions from the United States to Australia. These forces create a tailwind for companies building the foundational services,credible information, vetted provider networks, clinical workflow tools,that will be necessary if and when treatments scale.
Key adjacent and substitute markets include traditional telemedicine platforms, digital therapeutics (DTx) companies, and conventional venture capital funds focused on healthcare. The competitive threat or partnership potential from these established players is significant; a large telemedicine provider could easily add a psychedelic therapy directory, while a DTx company might build its own diagnostic tools. The regulatory landscape is the dominant macro force, with progress varying sharply by jurisdiction. Europe presents a patchwork of national regulations, while the U.S. FDA's review schedules for MDMA and psilocybin therapies set a critical timeline for the entire industry. Infrastructure builders must navigate this uncertainty, often focusing on near-term, legally permissible services like ketamine therapy, provider education, and media to establish traction ahead of broader regulatory change.
Given the absence of confirmed, third-party market sizing for the specific "psychedelic-care infrastructure" segment, the following table presents analogous market data that informs the potential scope.
| Market Segment | 2022/2023 Size | 2030 Projection | Source |
|---|---|---|---|
| Mental Health Apps (Global) | $5.2B | $17.5B | [Grand View Research, 2023] |
| Psychedelics Therapeutics (Global) | N/A | $6.1B - $10.75B | [Research and Markets, 2023] |
is that Pink Elephant is positioning within a high-growth, high-uncertainty adjacency. The driver is not the current size of the psychedelics market, but the anticipated need for trusted infrastructure to support its potential scaling. Success hinges less on capturing a defined SAM today and more on correctly timing regulatory milestones and building indispensable navigation tools for a confused patient and provider population.
Lightly corroborated -- Market sizing is drawn from third-party analyst reports for adjacent sectors, not the specific infrastructure layer. Demand drivers and regulatory context are supported by public health and clinical research sources.
Competitive Landscape
Sources and analysis Pink Elephant enters a market defined by a fragmented ecosystem of specialized players, positioning itself not as a direct competitor to any single product but as a venture builder and capital source aiming to orchestrate the infrastructure layer.
Given the absence of named direct competitors in the public record, the analysis must map the landscape by segment. The company's stated activities place it adjacent to several distinct categories. In venture capital, it faces established healthtech and psychedelic-focused funds like Atai Life Sciences' venture arm or Palo Santo. In digital health infrastructure, it touches markets served by provider directories like Zocdoc, telemedicine platforms like Cerebral, and mental health content hubs like Verywell Mind. Its specific focus on psychedelic-care navigation and education brings it near specialized media and clinic networks, such as those operated by Field Trip Health or the educational platform Psychedelic.Support. The competitive map is therefore a constellation of point solutions, each owning a specific piece of the patient or practitioner journey that Pink Elephant's model seeks to connect.
Where the subject may claim a defensible edge today is in its integrated scope and early-mover focus on the European regulatory frontier. By combining capital, venture building, media, and a proposed marketplace under one entity, it aims to create network effects between its portfolio companies and its own platforms like States of Mind [Pink Elephant]. This horizontal integration is rare among early-stage players, most of whom specialize. The edge is currently perishable, however, as it relies on unproven execution and the ability to attract quality founders and capital before larger, better-funded generalist VC firms or pharmaceutical companies decide to build similar integrated platforms. The durability of this edge hinges on securing proprietary deal flow and demonstrating tangible traction across its built ventures before the market consolidates.
The company is most exposed in two areas. First, it lacks the dedicated, deep therapeutic expertise and clinical trial experience of pure-play biotech or clinic operators, which could limit its credibility with top-tier researchers and regulators. Second, its capital base is unconfirmed; without a publicly disclosed fund size or institutional LP backing, it cannot compete on check size or follow-on capacity with established venture funds that are now allocating to mental health [Prospeo, April 2026]. A channel it does not own is the direct patient relationship at scale, which is currently captured by large telemedicine providers and employer health platforms.
The most plausible 18-month scenario sees the landscape bifurcating. A winner, should European psychedelic therapy regulations advance meaningfully in 2025-2026, would be any entity that has already built a trusted, compliant provider network and patient education hub. Pink Elephant's States of Mind platform could capture this role if it achieves critical mass [CB Insights]. A loser, should regulatory progress stall or incumbent telemedicine giants simply add psychedelic education modules to their existing platforms, would be any capital-light venture builder whose model depends on rapid regulatory change to validate its infrastructure bets. In that scenario, Pink Elephant's broad horizontal integration could become a liability, spreading resources too thinly without a dominant, revenue-generating core product.
Single unverified source -- Landscape analysis is inferred from company descriptions and adjacent market segments; no direct competitor intelligence or funding comparables are publicly verified.
Opportunity
Public sources The prize for a successful venture builder in progressive mental health is a portfolio of category-defining infrastructure companies, each capturing a slice of a market that could exceed $100 billion globally as psychedelic therapies move toward regulatory approval and mainstream adoption.
The headline opportunity is for Pink Elephant to become the foundational venture studio for the next-generation mental health ecosystem, analogous to a Y Combinator for psychedelic and progressive care. This outcome is reachable not because of current execution, but because of the structural gap it aims to fill. The company's stated focus on building across media, diagnostics, telemedicine, and provider marketplaces positions it to seed and scale multiple ventures that address the fragmented and nascent infrastructure of this emerging field [Pink Elephant]. If successful, it wouldn't just be a single company, but a generator of companies, capturing equity and strategic influence across the entire value chain from patient education to clinical delivery.
Growth would likely follow one of several concrete paths, each hinging on a specific catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Regulatory-First Platform | Pink Elephant's portfolio companies become the default compliance and data infrastructure for clinics as psychedelic therapies are approved in key markets like the EU and UK. | A major regulatory decision (e.g., MDMA-assisted therapy approval in Europe) creates urgent demand for vetted provider directories and treatment tracking software. | The company is already building PsyStandard, an initiative focused on safety and quality standards, indicating an early focus on the regulatory layer [Pink Elephant]. |
| Media-Led Consolidation | Its media arm, States of Mind, becomes the dominant patient education and lead-gen channel, allowing Pink Elephant to acquire or launch adjacent tools (marketplaces, diagnostics) with lower customer acquisition costs. | States of Mind achieves a critical mass of engaged users seeking reliable information, creating a proprietary funnel for its other ventures. | States of Mind is described as a platform providing honest information and connecting patients to providers, a model with precedent in other digital health verticals [CB Insights]. |
| Specialist Venture Capital | The Pink Elephant Venture Fund emerges as the go-to early-stage capital source for psychedelic infrastructure, giving it unparalleled deal flow and the right of first refusal on the most promising teams. | The fund secures a cornerstone institutional LP, providing the credibility and capital to anchor competitive rounds. | The company publicly describes a seed investment program targeting SaaS for clinics and telemedicine, signaling intent to play an active capital role [Psychedelic Health, May 2024]. |
Compounding for a venture builder looks different than for a single product company. A successful initial investment or incubated company, such as a provider marketplace, generates not just returns but also proprietary data on clinic operations and patient journeys. This data can de-risk subsequent investments in adjacent areas, like diagnostic tools or clinician training software. Furthermore, a reputation for successful company-building attracts stronger founder talent, creating a virtuous cycle where the best ideas seek out Pink Elephant's capital and operational support first. There is a suggestion this may be starting, with a product manager's profile citing experience scaling a provider network to over 300 clinics and therapists, though it is not clear if this was a prior or current Pink Elephant project [LinkedIn].
The size of a win is best framed by looking at the value of the pieces, not the whole. For example, a successful standalone provider marketplace and telemedicine platform in this space could aim for a valuation comparable to companies like Alma or Headway, which reached unicorn status by facilitating access to mental health care. A portfolio containing several such companies, even at earlier stages, could represent significant aggregated equity value. In a scenario where the regulatory-first platform plays out, and Pink Elephant successfully incubates the market's leading compliance software provider, a credible outcome might be a company worth several hundred million dollars, based on valuations for healthcare compliance SaaS in adjacent regulated fields. This is a scenario-specific outcome, not a forecast, but it illustrates the potential scale embedded in the venture-building model if execution aligns with market timing.
Lightly corroborated -- The opportunity analysis is based on the company's stated model and cited market dynamics, but specific catalysts and compounding effects are inferred from public positioning rather than observed results.
Sources
Public sources
[Pink Elephant, October 2026] Pink Elephant | https://pink-elephant.co/
[LinkedIn, retrieved 2026] Yuri Filatov - co-founder and CEO | https://www.linkedin.com/in/filalogic
[Remocate, September 2025] CMO for Pink Elephant VC | https://www.remocate.app/jobs/cmo-3
[RigorBiz, October 2025] Pink Elephant, Unipessoal Lda | https://www.rigorbiz.pt/pink-elephant-unipessoal-lda
[Psychedelic Health, May 2024] Pink Elephant launches a seed investment program for startups in the psychedelics space | https://www.psychedelic.health/ (URL inferred from source context; specific article path not provided in research)
[CB Insights] States of Mind addresses the gap in mental health care with a provider directory and media platform | https://www.cbinsights.com/ (URL inferred from source context; specific company profile path not provided in research)
[Yuri Filatov LinkedIn, retrieved 2026] Yuri Filatov has 15+ years of experience building from the ground up | https://www.linkedin.com/in/filalogic
[Crunchbase] Fatima Cabral - Co-Founder and CEO @ Pink Elephant | https://www.crunchbase.com/person/fatima-cabral-2a09
[Prospeo, April 2026] Pink Elephant | https://prospeo.io/c/pink-elephant
[Grand View Research, 2023] Mental Health Apps Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/ (URL inferred from source context; specific report path not provided in research)
[Research and Markets, 2023] Psychedelic Drugs Global Market Opportunities and Strategies | https://www.researchandmarkets.com/ (URL inferred from source context; specific report path not provided in research)
[World Health Organization, 2022] World mental health report: transforming mental health for all | https://www.who.int/publications/i/item/9789240049338
[Nature Medicine, 2021] Trial of Psilocybin versus Escitalopram for Depression | https://www.nature.com/articles/s41591-021-01336-3
Articles about Pink Elephant
- Pink Elephant's Venture Builder Aims for the Psychedelic Clinic's Waiting Room — The Lisbon-based firm is assembling a portfolio of media, diagnostics, and provider navigation tools ahead of broader regulatory shifts.